Business
Jasper Therapeutics Strengthens Management Team with Key Appointments
Patricia Carlos Appointed Senior Vice President of Regulatory Affairs and Quality Annette Marcantonio Appointed Vice President of Clinical Operations REDWOOD

About this update from Jasper Therapeutics, Inc.
[{"type":"text","content":"Patricia Carlos Appointed Senior Vice President of Regulatory Affairs and Quality Annette Marcantonio Appointed Vice President of Clinical Operations REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of two seasoned pharma industry executives to its regulatory affairs, quality and clinical operations leadership teams. Patricia Carlos joins Jasper as the company's Senior Vice President of Regulatory Affairs and Quality, and Annette Marcantonio was appointed as Vice President of Clinical Operations. “With multiple clinical studies of briquilimab in Chronic Spontaneous Urticaria, Low to Intermediate Risk MDS and hematopoietic stem cell transplant either ongoing or planned to start this year, it is the right time to add strength and depth to our regulatory, quality and clinical operations teams,” said Ronald Martell, Chief Executive Officer of Jasper. “Patty and Annette bring decades of experience in guiding drug development programs from investigational new drug application through to successful commercialization, and we are delighted to welcome them to the Jasper organization.” Patricia Carlos has over 25 years of experience in the biotech and pharmaceutical industry, with a proven track record of success in driving global strategy, regulatory affairs, and strategic partnerships. Her expertise spans early development through approval and post-marketing in multiple therapeutic areas. Prior to joining Jasper, she was Chief Regulatory, Quality and Safety Officer at Agenus, an immuno-oncology company. Previously, she served as Senior Vice President of Regulatory and Quality at Arcus Biosciences, where she built out the Regulatory, Quality and Safety functions and led the global regulatory strategy. Prior to Arcus, Patty held leadership roles at Bellicum Pharmaceuticals, BeiGene, Medivation-Pfizer, Gilead Sciences, and Bayer. Patricia received her bachelor's degree from Memorial University of Newfoundland. Annette Marcantonio has spent more than 30 ye...